Hospital Clinico San Carlos
Verified site
Madrid, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on adults who have kidney problems caused by an abnormal immune protein called IgA. These conditions include lupus nephritis, IgA nephropathy, and IgA vasculitis nephritis, which can lead to blood or protein appearing in the urine and may gradually damage kidney function. The medication being tested is Nebaprubart (code name JJP-1212), which is given by an intravenous (through a vein) infusion, meaning the drug is slowly dripped into the bloodstream.
The purpose of the study is to assess the safety, tolerability and how well the drug works in these kidney diseases. Participants will receive a series of infusions over several months, with regular check‑ups that include blood tests (such as serum creatinine, a measure of kidney function), urine collections to calculate the urine protein to creatinine ratio (a way to see how much protein is lost in the urine), heart rhythm recordings (ECG), and physical examinations. Researchers will also look for any anti‑drug antibodies, which are signs that the body’s immune system is reacting to the medicine, and will record any adverse events, meaning any unwanted side effects that occur during the trial.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
16 criteria
36 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Madrid, Spain
Leuven, Belgium
Gent, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Nebaprubart is an experimental medicine that is given through an IV (intravenous) infusion. It is a liquid concentrate that is mixed with a solution before being administered. In this trial, the drug is being tested in adults who have kidney problems caused by abnormal IgA antibodies, such as lupus nephritis, IgA nephropathy, or IgA‑related vasculitis kidney disease. The main goal is to see whether Nebaprubart is safe to use, how well patients can tolerate it, and whether it helps improve kidney function in these conditions. Because it is an orphan drug, it is being studied for a disease area that has few treatment options.
It is kidney inflammation caused by systemic lupus erythematosus. The immune system attacks the kidney’s filtering units, leading to swelling and damage. Over time, protein may leak into urine and kidney function can gradually decline. Flare-ups can increase inflammation, while periods of lower activity may have fewer symptoms. The disease can affect both kidneys and may become chronic if not controlled.
It is a kidney condition where deposits of the antibody IgA build up in the glomeruli. These deposits cause inflammation and scarring of the filtering structures. As the scarring progresses, protein and blood may appear in the urine and kidney function can slowly worsen. Episodes of increased blood in urine often follow infections of the throat or gut. The disease can remain stable for years or advance gradually.
This disorder involves inflammation of small blood vessels throughout the body, accompanied by IgA deposits in the kidneys. The kidney involvement leads to swelling, blood and protein in the urine, and gradual loss of filtering ability. Skin rash, joint pain, and abdominal pain may appear before kidney signs. Kidney damage can increase over time, especially after repeated episodes of vessel inflammation. The condition may persist or improve, but kidney changes can become permanent.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.